KeyMed Biosciences (HKEX: 02162) today announced the National Medical Products Administration (the 'NMPA') of China has recently approved the supplemental New Drug Application (the 'sNDA') of ...

The money will pay for efforts to prevent and treat opioid addiction, or fund services that help people in recovery.

Despite the recently reported national decline in opioid overdose deaths, many U.S. communities, including New Orleans, continue to see an ...

Nasal irrigation can be a useful addition to the management of chronic upper respiratory conditions, including nasal ...

The state’s top lawyer accused a British multinational drug company of “deceptive and unfair practices” that endangered lives and exploited American taxpayers.

The USPTO has granted a patent to Vistagen’s non-opioid oral product candidate AV-101 for neuropathic pain treatment.

Nandita Vijayasimha, Bengaluru Thursday, February 6, 2025, 08:00 Hrs [IST] ...

Purdue has sold a Narcan alternative since 2022 and Hikma has developed an opioid antagonist twice the dose of Narcan.

In a Phase IIb trial, GH001 elicited significant drops in treatment-resistant depression. The news comes less than two weeks ...

Padagis®, a leading generic manufacturer, announced today it is lowering the price of its over-the-counter (OTC) 4 mg ...

The FDA has accepted for review the NDA for bumetanide nasal spray for edema associated with CHF, as well as hepatic and renal disease.

The Food and Drug Administration recently expanded approval for Spravato, an antidepressant nasal spray used to treat ...